Atherosclerosis Plus

❤️ Today, we celebrate FH Awareness Day! Our message this year is clear: early detection and optimal management of familial hypercholesterolaemia (FH) can change the course of a lifetime. But making a lasting difference takes more than awareness. It requires shared responsibility, strong collaboration, and coordinated action - working together to ensure people with FH are identified early and receive the care they need. Together, we can turn awareness into action and help build a healthier future, aligned with the EU Safe Hearts Plan. 🔗 Learn more: eas.to/FHWeek2026 #FHWeek #FindFH #FHAware #FHAware2026

Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD). FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood. 🚨 Early diagnosis and treatment can dramatically improve — and even normalize — life expectancy. Yet, fewer than 10% of affected children in Europe are currently identified. The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights: ✔️ Improved diagnostic criteria ✔️ Earlier treatment initiation — sometimes from age 6 ✔️ Lower LDL-C treatment targets ✔️ New lipid-lowering therapies ✔️ Updated treatment algorithms ✔️ Better transition from paediatric to adult care The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age. Read the full publication: eas.to/consensus-fhinchildre… To the press release: eas.to/consensus-fhinchildre… To the key messages: eas-society.org/publications…

📚 EAS members enjoy exclusive access to our official journals – a key benefit of membership! 🔬 @ATHjournal – our official journal – publishes cutting-edge research on lipids, vascular biology, and cardiovascular disease. ✅ Free full access for members ✅ 25% discount on open-access publication fees 👉 Don’t forget to follow Atherosclerosis on social media  for the latest updates! 🔗 sciencedirect.com/journal/at… 🧬 @ATH_Plus – our open-access journal – features high-quality original articles, reviews, and case reports on the mechanisms and prevention of atherosclerosis. 🔗sciencedirect.com/journal/at… Stay informed. Stay connected. Publish with impact. All included in your EAS membership. 🔗 Learn more about EAS membership here: eas-society.org/society-affa… Jan Boren, Florian Kronenberg Laura Calabresi @FedericaFogacci Katariina Öörni

Just published! The new EAS Consensus Statement introduces a practical clinical staging system for metabolic disorders—helping healthcare professionals act earlier and more precisely to improve long-term outcomes. Hear from Co-Chair Professor Stefano Romeo on why this matters. Read the full article: eas-society.org/publications… @stefano_romeo76, @mansoor_husain, @VidalPuig, @ProfKausikRay, @LaleTokgozoglu, @j_rvl, @cj_binder

In this issue of EAS newsletter you can read: eas.to/NewsFeb11_2025T 🧐 Education: Don't miss a must-attend EAS webinar! Explore cardiovascular challenges in androgen therapies 🧐 Congress: Take advantage of the early-bird rate, available until March 4 🧐 Education: Targeting inflammation in cardiovascular disease: is the evidence strong enough? 🧐 Outreach: Building momentum: join the EAS-LIPRA newsletter to stay ahead in lipidology and preventive cardiology research across Africa 🧐 Society: EAS Calendar – February-March 2025 @ProfKausikRay @KatiOorni

Abstract submission for the 48th European Lipoprotein Club Meeting is now open! Don’t miss this opportunity to showcase your research, connect with experts, and shape the future of lipoprotein science. Submit your abstract today: eas-elc.org/abstract-submiss… @ProfKausikRay @KatiOorni

Join us for an exclusive episode of AtheroTalk with Prof. Paul Ridker, recipient of the Anitschkow Prize 2025. Discover his insights on tackling personal challenges, exploring groundbreaking frontiers in cardiovascular disease research, and his inspiring advice for young scientists: "Try to find out what you’re actually really good at and find a problem that excites you!" 🎧 Spotify: eas.to/ATHTalkE05S 🎧 Apple Podcasts: eas.to/ATHTalkE05A 🎧 Youtube: eas.to/ATHTalkE05Y @ProfKausikRay @KatiOorni

In episode 3 of AtheroTalk, we spoke with Prof. Nicola Ferri about his inspiring academic journey. Our conversation highlighted the profound impact of mentors in shaping a researcher’s path and how these valuable relationships often endure for years, continuing to influence and inspire. - Spotify: eas.to/ATHTalkE03S - Apple Podcasts: eas.to/ATHTalkE03A @ProfKausikRay @KatiOorni

Refresh your expertise and broaden your perspective! Talks from the third EAS-LatAm webinar are now available for you to explore at your leisure. 🔍 Potential atherogenicity of tryglyceride-rich lipoproteins: eas.to/LatAmWeb3T1 🔍 TG-rich lipoproteins: stars or second advantage in the field of residual CV risk?: eas.to/LatAmWeb3T2 @ProfKausikRay @KatiOorni